Education
About Us
Working with TipRanks
Follow Us
Arch Therapeutics (GB:0HHJ)
LSE:0HHJ
Total Valuation
Arch Therapeutics has a market cap or net worth of $444.00. The enterprise value is ―.
Market Cap$444.00
Enterprise Value―
Share Statistics
Arch Therapeutics has 4,444,364 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,444,364
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Arch Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee9.47K
Profits Per Employee-872.85K
Employee Count8
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Arch Therapeutics is ―. Arch Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Arch Therapeutics had revenue of 75.72K and earned -6.98M in profits. Earnings per share was -2.27.
Revenue75.72K
Gross Profit-2.44K
Operating Income-5.04M
Pretax Income-6.98M
Net Income-6.98M
EBITDA-3.88M
Earnings Per Share (EPS)-2.27
Cash Flow
In the last 12 months, operating cash flow was -3.70M and capital expenditures -4.52K, giving a free cash flow of -3.71M billion.
Operating Cash Flow-3.70M
Free Cash Flow-3.71M
Free Cash Flow per Share-0.83
Dividends & Yields
Arch Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change-77.38%
50-Day Moving Average0.18
200-Day Moving Average0.61
Relative Strength Index (RSI)0.00
Average Volume (3m)0.00
Important Dates
Arch Therapeutics upcoming earnings date is May 14, 2019, TBA Not Confirmed.
Last Earnings DateFeb 1, 2019
Next Earnings DateMay 14, 2019
Ex-Dividend Date―
Financial Position
Arch Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Arch Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate―
Enterprise Valuation
Arch Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Arch Therapeutics has $30.03K in cash and marketable securities with $0.00 in debt, giving a net cash position of $9.36M billion.
Cash & Marketable Securities$30.03K
Total Debt$0.00
Net Cash$9.36M
Net Cash Per Share$2.11
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Arch Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―